Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8353370 | 1.00 | ADRB2 (0.52) | ADRB2ALDH1A1FFAR2SLC6A4HTR2A | |
| SCHEMBL2669157 | 1.00 | ADRB2 (0.52) | ADRB2ALDH1A1FFAR2SLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL20303159 | 0.98 | ADRB2 (0.50) | ADRB2ALDH1A1FFAR2SLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL20303161 | 0.98 | ADRB2 (0.50) | ADRB2ALDH1A1FFAR2SLC6A4HTR2A | |
| SCHEMBL2669165 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GAASMN1; SMN2HIF1ALMNA | |
| SCHEMBL19286210 | 0.82 | ADRB2 (0.54) | ADRB2ALDH1A1FFAR2HPGDGAA | |
| SCHEMBL28277737 | 0.82 | ADRB2 (0.54) | ADRB2ALDH1A1FFAR2HPGDGAA | |
| SCHEMBL11633101 | 0.78 | ADRB2 (0.56) | ADRB2ALDH1A1FFAR2HPGDGAA | |
| SCHEMBL10087172 | 0.78 | ADRB2 (0.56) | ADRB2ALDH1A1FFAR2SLC6A4HPGD | |
| SCHEMBL10315779 | 0.78 | ADRB2 (0.56) | ADRB2ALDH1A1FFAR2SLC6A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3789378-A1 | PIPERIDINES OR PIPERIDONES SUBSTITUTED WITH UREA AND HETEROARYL | Grünenthal GmbH (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| WO-2014042939-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-8124634-B2 | CB1 receptor modulators | 7TM PHARMA A/S (DK) | 2012-02-28 | — | — | US | disclosed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-7879902-B2 | Psychological disorders; eating disorders; metabolism disorders; cognition activators; alcoholism; drug abruse thereapy | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| WO-2010131669-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
| US-7772190-B2 | Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same | BAYER ANIMAL HEALTH GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| US-7763634-B2 | Inhibitors of janus kinases | MERCK & CO., INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| EP-0355351-B1 | Process for the preparation of amines | BAYER AG (DE) | 1993-11-10 | — | — | EP | disclosed |
| US-5011996-A | Process for the preparation of amines | BAYER AKTIENGESELLSCHAFT (DE) | 1991-04-30 | — | — | US | disclosed |
| EP-0355351-A2 | Process for the preparation of amines | BAYER AG (DE) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | ADRB2 1999/4885ALDH1A1 2435/4885FFAR2 259/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ADRB2 52/4885ALDH1A1 1120/4885FFAR2 2943/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | ADRB2 1930/4885ALDH1A1 3084/4885FFAR2 258/4885 |
| US-20120059012-A1 | 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACSL3, SLCO4C1, SLC38A7 | ADRB2 949/4885ALDH1A1 96/4885FFAR2 311/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | ADRB2 1047/4885ALDH1A1 2333/4885FFAR2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.